Additive effect of bunazosin on intraocular pressure when topically added to treatment with latanoprost in patients with glaucoma

The additive effects on intraocular pressure of combining nipradilol 0.25% and latanoprost 0.005% ophthalmic solutions: a prospective, randomized, multicenter study

“…When bunazosin (α 1 blocker) was added to latanoprost, an 8.2% increase was seen (baseline with latanoprost monotherapy, 18.2 mmHg). 21 In the present study, mean IOP during latanoprost monotherapy was a relatively low 14.9 mmHg, and adding nipradilol lowered IOP by an additional 6.5%. The relatively low IOP of latanoprost monotherapy suggests that the additive effects of nipradilol to latanoprost on IOP are comparable to those of other drugs.…”

“…That mean IOP significantly decreased to 14.9 ± 2.4 mmHg (23.7% decrease) during monotherapy (weeks [4][5][6][7][8][9][10][11][12]. During combination therapy (weeks [16][17][18][19][20][21][22][23][24], the mean IOP decreased even further, to 13.8 ± 1.9 mmHg (29.0% decrease from baseline), a signifi cant reduction in IOP, with a further decrease of 1.2 ± 1.1 mmHg (6.5%) over monotherapy. In the prior nipradilol group, the mean baseline IOP was 20.2 ± 3.1 mmHg, and this signifi cantly decreased to 16.7 ± 3.5 mmHg (17.1% decrease) during monotherapy (weeks [4][5][6][7][8][9][10][11][12].…”

“…In the prior nipradilol group, the mean baseline IOP was 20.2 ± 3.1 mmHg, and this signifi cantly decreased to 16.7 ± 3.5 mmHg (17.1% decrease) during monotherapy (weeks [4][5][6][7][8][9][10][11][12]. Again, during combination therapy (weeks [16][17][18][19][20][21][22][23][24], the mean IOP decreased to 14.3 ± 3.1 mmHg (28.1% decrease from baseline), a signifi cant reduction in IOP, with a further decrease of 2.5 ± 1.5 mmHg (15.0%) over monotherapy.…”

“…9 It has also been reported that latanoprost and bunazosin have additive IOP-lowering effect. 21 Therefore, we think that the effectiveness of latanoprost and nipradilol in IOP lowering is because they act to increase uveoscleral outfl ow.…”

Ocular Hypotensive Effects of Anti-Glaucoma Agents in Mice

“…These anti-glaucoma agents reduce the human IOP with a relatively short duration of action, and are accordingly administered 2 to 4 times a day in humans. [17][18][19][20] Broadly speaking, therefore, in terms of the durations of the ocular hypotensive effects of the present anti-glaucoma agents, there is a good correlation between mouse and human.…”